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Porcine circovirus type 2 (PCV2) is considered generally to be the
primary causative agent of postweaning multisystemic wasting
syndrome (PMWS), which has become a serious economic problem
for the swine industry worldwide. PCV2 is a small non-enveloped
virus with a single-stranded circular DNA genome of approximately
1.7 kb in size that belongs to the genus Circovirus, in the family
Circoviridae (Finsterbusch andMankertz, 2009; Mankertz et al., 1997;
Studdert, 1993; Todd et al., 1991). Its genome contains at least two
potentially functional open reading frames (ORFs): ORF1 (945 nt)
encodes the Rep protein involved in viral replication and ORF2 (702
nt) encodes the immunogenic capsid (Cap) protein (Cheung, 2003;
Fenaux et al., 2002; Guo et al., 2010; Nawagitgul et al., 2000). PMWS
was ﬁrst recognized in Canada in 1997, and then subsequently
identiﬁed in pigs in other countries (Harding and Clark, 1997;
Mankertz et al., 2000; Wellenberg et al., 2004). Recently, a system
of nomenclature was proposed for PCV2 that took into account the
classiﬁcation of Grau et al. (2008) and identiﬁed twomajor genotypes
of the virus (PCV2a and PCV2b) that are circulating worldwide and a
third genotype (PCV2c) that was reported sporadically in the 1980s
(Cortey et al., 2011; Grau et al., 2008; Segalés et al., 2008). A numberof studies have demonstrated that genotype PCV2b is more
predominant than PCV2a in pig herds, and PCV2 has undergone
much genetic variation in recent years (Choi and Chae, 2008; Dupont
et al., 2008; Guo et al., 2010; Jantafong et al., 2011; Knell et al., 2005; Li
et al., 2010; Nielsen et al., 2003; Olvera et al., 2007; Wang et al., 2009;
Wen et al., 2005). In addition, a recent report revealed the emergence
of a new type of PCV, a recombinant between PCV1 and PCV2 (Gagnon
et al., 2010). However, information regarding recombination between
different genotypes of PCV2 remains limited. In this study, two
recombinantmutants of PCV2 resulted from genetic replacement after
co-infection with genotypes PCV2a and PCV2b in vitro.
Results
Isolation and identiﬁcation of two PCV2 recombinant mutants
The existence of the recombinant genomic sequences of PCV2,
which resulted from replacement of a genomic fragment containing
open reading frame 2 (ORF2) of genotype PCV2b with that of
genotype PCV2a, was detected ﬁrst in the supernatant of the freeze–
thawed cell cultures from the co-infection with PCV2a and 2b
genotype viruses in vitro. This occurred at the 3rd passage for the
PCV2a/CL1 plus PCV2b/JF11 strains co-infection group and the 4th
passage for the PCV2a/CL1 plus PCV2b/YJ strains co-infection group,
respectively. No sequence of the recombinant PCV2 was detected
among the 10 selected clones in the ﬁrst two or three passages (two
passages for the PCV2a/CL1 plus PCV2b/JF11 co-infection group and
three passages for the PCV2a/CL1 plus PCV2b/YJ co-infection group,
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selected sequences were all the same as those of the parental strains.
Afterwards, the proportion of the recombinant genomic sequences
among the sequences from the 10 selected clones became higher with
each consecutive passage in vitro, from 20% (2/10) at the 3rd passage
or the 4th passage (for the PCV2a/CL1 plus PCV2b/JF11 co-infection
group and the PCV2a/CL1 plus PCV2b/YJ co-infection group, respec-
tively) to 100% (10/10) at the 7th passage for both co-infection
groups. The number of the recombinant sequences as a proportion of
the parental sequences in the 10 selected clones from each passage
(10 passages in total) is indicated in detail in Table 1. Two
recombinant mutants of PCV2 showed higher replication efﬁciencies
compared with their parental strains, and therefore they could be
separated from the parental PCV2 by the consecutive end-point
dilution method. These mutants were conﬁrmed by an immunoper-
oxidase monolayer assay (IPMA) performed according to a method
described previously (Huang et al., 2011). Replacement of the
genomic sequence from 1018 nt to the end of the viral genome
(1767 and 1766 nt for PCV2b/JF11 and PCV2b/YJ, respectively) of the
PCV2b genotype with the corresponding sequence from the PCV2a
genotype was conﬁrmed by sequence analysis using the DNAMAN
software (Version 5.2.2, Lynnon Biosoft, 1994), and schematic
diagrams were drawn using DNAMAN software (Fig. 1). The two
PCV2 recombinant mutants contained ORF1 from PCV2b and ORF2
from PCV2a. They were classiﬁed according to the nomenclature
proposed by Grau et al. (2008), which indicates the origin of ORF1 ﬁrst
and the origin of ORF2 second, and were designated PCV2b(JF11)/2a
(CL1) and PCV2b(YJ)/2a(CL1), respectively. The percentage nucleo-
tide identity for the entire viral genome of the recombinants
compared with the parental strains was 98.47% for PCV2a/CL1 and
96.72% for PCV2b/JF11 for recombinant PCV2b(JF11)/2a(CL1); and
98.70% for PCV2a/CL1 and 96.61% for PCV2b/YJ for recombinant
PCV2b(YJ)/2a(CL1). Moreover, the two recombinant mutants were
both reactive with the sera from pigs infected with PCV2a and PCV2b
genotypes by IPMA, respectively, and no signiﬁcant differences were
shown (Fig. 2). Information relating to the two PCV2 recombinant
mutants, as well as the parental strains used in this study, is
summarized in Table 2. The two PCV2 recombinant mutants had an
approximate diameter of 17 nm, as determined by electron micros-
copy (Fig. 3).
PCV2 recombinant mutants showed greatly enhanced viral
replication efﬁciency
In general, the two PCV2 recombinant mutants that were based on
the PCV2b genotype backbone replicated to higher infectivity titers
throughout the study when compared with the parental virus. TheTable 1
The proportions of the recombinant sequences to the parental virus sequences in the 10
selected clones of each passage.
Passage PCV2a/CL1 plus PCV2b/JF11
co-infection group
PCV2a/CL1 plus PCV2b/YJ
co-infection group
Recombinant/parental# Recombinant/parental#
1 0/10 0/10
2 0/10 0/10
3 2/8 0/10
4 4/6 2/8
5 8/2 7/3
6 9/1 8/2
7 10/0 10/0
8 10/0 10/0
9 10/0 10/0
10 10/0 10/0
Note: #: represents the proportions of the recombinant sequences to the parental
sequences in the 10 selected clones for each passage from PCV2a/CL1 plus PCV2b/JF11
co-infection group and PCV2a/CL1 plus PCV2b/YJ co-infection group, respectively.two PCV2 recombinant mutants achieved signiﬁcantly higher titers in
PK15 culture than any parental PCV2 strain at 24, 48, 60, 72 and 84 h
post-infection (pi), and this difference was found to be statistically
signiﬁcant (Pb0.05) by t-test. Taken together, the two PCV2
recombinant mutants [PCV2b(JF11)/2a(CL1) and PCV2b(YJ)/2a
(CL1)] were found to have signiﬁcantly higher replication efﬁciencies
than either parental virus (PCV2a or PCV2b) in vitro (Fig. 4).
Phylogenetic tree analysis of the whole genome for the two PCV2
recombinant mutants and their parental viruses
In order to show the weight of the Cap gene variation in the whole
genome sequence, phylogenetic trees were constructed on the basis of
the whole genomic DNA sequences of the PCV2 strains used in this
study, together with those of three reference sequences representing
different genotypes, using the MEGA 3 software. The genotypes of the
two PCV2 recombinant mutants had changed from PCV2b to PCV2a,
although their parental backbones, PCV2b/JF11 and PCV2b/YJ, were
both of the PCV2b genotype (Fig. 5). These ﬁndings were based on
classiﬁcation according to the nomenclature proposed by Grau et al.
(2008); Segalés et al. (2008) and Cortey et al. (2011).
Signiﬁcant differences in antigenicity between the two recombinant
mutants and their parental viruses
The capture ELISA results showed that PCV2a/CL1, as well as the
two PCV2 recombinant mutants PCV2b(JF11)/2a(CL1) and PCV2b
(YJ)/2a(CL1), had strong reactivity with monoclonal antibody (mAb)
1D2, whereas the other parental PCV2 strains (PCV2b/JF11 and
PCV2b/YJ) did not. These results indicate that mAb 1D2 detected an
epitope of the Cap protein. The two PCV2 recombinant mutants,
which resulted from recombination between different genotypes of
PCV2a and 2b, exhibited signiﬁcant antigenic changes within the
PCV2 Cap protein, and did not inherit the antigenic properties of the
parental backbone, PCV2b/JF11 or PCV2b/YJ, but instead inherited
those of the parental donor, PCV2a/CL1 (Fig. 6).
Sensitive serum neutralization assays
The serum neutralization assay revealed that the recombinant
mutants and their parental strains could all be neutralized by the
PCV2-positive sera from pigs infected with either the PCV2a or the
PCV2b genotype. However, the titers of the PCV2-positive sera from
pigs infected with the PCV2a or PCV2b genotype against the
recombinant mutants and their parental strains were not identical
(from 1: 800 to 1: 12,800). In addition, for mAb 1D2 only the parental
PCV2a/CL1 and recombinant mutants could be neutralized with the
same neutralization titer (1: 640), and the other two parental strains
could not be neutralized by mAb 1D2. Differences in the antigenicity
of the two recombinant mutants and their parental strains were
shown (Table 3). The PCV2a sera recognized the recombinants better
than the PCV2b parental strain (1: 6400 vs 1: 1600/1: 3200) and the
PCV2b sera recognized the PCV2b parental strain better than the
recombinants (1: 3200/1: 6400 vs 1: 800/1: 1600). This indicates that
much of the antigenicity resides in ORF2 and is exchanged after
recombination of the viruses. This could also imply that a recombinant
could decrease its antigenicity in vivo, and this could give an
advantage in escaping from the immune response.
Discussion
PCV2 is the major swine pathogen associated with porcine
circovirus-associated diseases (PCVADs), including PMWS (Allan et
al., 1998). The molecular mechanisms of PCV2 replication and
pathogenesis are poorly understood, but PMWS associated with
PCV2 infection has become an economically important global disease
Fig. 1. Schematic diagram of the two PCV2 recombinant mutants resulting from genomic replacement between the parental backbone PCV2 (PCV2b/JF11 and PCV2b/YJ) and the
parental donor PCV2a/CL1. Replacement of genomic sequences from 1018 nt to the end of the viral genome (1767 and 1766 nt for PCV2b/JF11 and PCV2b/YJ, respectively) of the
PCV2b genotypes with the corresponding region from the PCV2a genotype was conﬁrmed by sequence analysis using the DNAMAN software.
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mutants of PCV2 with signiﬁcantly enhanced viral replication and
altered antigenicity in vitro.
Different genotypes of PCV2 have been reported worldwide;
however, information regarding recombination between PCV2 iso-Fig. 2. Antigenic identiﬁcation of the recombinant mutants by screening the reactivity
immunoperoxidase monolayer assay (IPMA). The two recombinant mutants were both r
respectively, and no signiﬁcant differences were shown. Their parental PCV2 strains andmoc
with the PCV2a genotype; and [S2b]: PCV2-positive sera from pigs infected with the PCV2blates of different genotypes is limited to ﬁeld sample sequencing
studies and the phenomenon has not been demonstrated previously
in vitro.
This study investigated recombination between different geno-
types of PCV2 and characterized the recombinant mutants in vitro.with sera from pigs infected with different PCV2 genotypes, respectively, using an
eactive with the sera from pigs infected with PCV2a and PCV2b genotypes by IPMA,
k-infected PK15 cells were used as controls. [S2a]: PCV2-positive sera from pigs infected
genotype.
Table 2
Characterization of two recombinant mutants of PCV2 and their parental viruses.
PCV2 strains
Parental viruses Recombinant mutants
PCV2a/CL1 PCV2b/YJ PCV2b/JF11 PCV2b(JF11)/2a(CL1) PCV2b(YJ)/2a(CL1)
GenBank No JF682791 HM038032 JF682792 JF682793 JF682794
Genotype PCV2a PCV2b PCV2b PCV2a PCV2a
Passagea 9 9 9 – –
Year of isolation 2010 2008 2010 2011 2011
Genome length (nt) 1768 1766 1767 1768 1768
ORF1 length (nt) 945 945 945 945(PCV2b/JF11)b 945(PCV2b/YJ)b
ORF2 length (nt) 702 708 702 702(PCV2a/CL1)b 702(PCV2a/CL1)b
Number of amino acidsc 0 2 (N and E) 0 0 0
a Represents the number of passage of the parental viruses used for co-infection in this study.
b Indicates that the ORF is identical to the parental PCV2 strain, as shown in brackets.
c Represents the elongation number of amino acids (aa) encoded by ORF2 compared with classical PCV2 strains with 233 aa in the ORF2-encoded Cap protein.
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PCV2b/JF11 and PCV2b/YJ, respectively, with PCV2a/CL1 in PK15 cells
in vitro. The two recombinants were only detected at the 3rd or 4th
passage after co-infection. It is possible that the proportion of the
PCV2 recombinant mutants in the ﬁrst two or three passages was very
low and could not be detected at that time. Recombinant PCV2
propagated more quickly than the parental strains, and therefore
became predominant in the co-infectionmixture from the 7th passage
in vitro. Replacement of genomic fragments, including the entire
ORF2, in different genotypes of PCV2 has been detected all over the
world. The emergence of a new type of porcine circovirus, a
recombinant between PCV1 and PCV2, has been reported in pigs in
Canada (Gagnon et al., 2010). It can be speculated, therefore, that
recombinant mutants among different genotypes may become
dominant worldwide in the future, although such reassortments
have only occurred in vitro in this study, to date. The antigenicities, as
well as the replication efﬁciencies, of these PCV2 recombinant
mutants were greatly changed when compared with their parental
strains, as determined by in vitro experiments. The two PCV2
recombinant mutants had much higher replication efﬁciencies than
any of the parental PCV2 strains, which suggests that the virulence of
the recombinant mutants may have been enhanced through genetic
recombination. The results mentioned above were obtained in PK15
cells. In addition, antigenic variation was evident in the recombinant
PCV2 mutants, as demonstrated by the signiﬁcant changes in
reactivity with neutralizing mAb 1D2, which also reﬂected genetic
variation in these mutant strains. Moreover, the titers of the PCV2-
positive sera from the PCV2a or PCV2b genotype against the
recombinant mutants and their parental strains were not identical,Fig. 3. Immune electron micrograph of negatively stained PCV2 recombinant mutant
particles (bar=100 nm). The diameter of the particles was about 17 nm, conﬁrming
previous reports.which indicates that the recombinant mutants may demonstrate
increased virulence and adaptation to the cell culture by escaping
neutralization by the host immune system. In future, other PCV2
recombinant mutants may emerge that result from recombination
between different genotypes of PCV2; these may exhibit enhanced
virulence and may become predominant worldwide.
Previous investigations have identiﬁed two amino acid mutations
(P110A and R191S) within the PCV2 capsid protein that are important
for PCV2 attenuation in vivo and for enhanced growth in PK15 cells,
when compared with the wild-type parental virus (Fenaux et al.,
2004). However, we report herein two recombinant mutants with no
amino acid or nucleotide mutations when compared with their
parental viruses. Allan et al. (1994) attempted to infect Vero cells with
PCV1, and intranuclear immune staining, characteristic of PCV1
replication, was not detected until the 6th cell culture passage in
Vero cells. By the 15th passage, PCV1 had replicated in Vero cells to a
level similar to that in PK15 cells, which suggests that efﬁcient
replication of PCV1 in Vero cells depends upon the number of viral
passages. It would be interesting to see whether additional passages
in PK15 cells can enhance the growth of PCV2 further. In this study, a
lower number of passages (nine) of the parental viruses with
relatively low titers, below 104.0 TCID50 per ml in PK15 cells, were
used for co-infection. Surprisingly, it was only at the 6th passage that
the two PCV2 recombinant mutants reached titers above 105.0 TCID50
per ml in PK15 cells. Taken together, these results show that the key
phenotype changes, characterized by signiﬁcantly enhanced viral
replication and altered antigenicity in vitro, were not the same as
those mentioned above. The signiﬁcance of PCV2 recombination in
terms of circovirus-associated pathogenesis is unclear. The virulence
properties of PCV2 appear to be located in the capsid protein. For
example, Fenaux et al. (2004) reported that the attenuation that
occurred following serial passage of an isolate of PCV2 was the result
of mutations in the capsid protein. However, the same group (Fenaux
et al., 2003) reported that a chimera incorporating ORF1 of PCV1 and
ORF2 from PCV2 was non-pathogenic in pigs. It is not a single ORF1
gene or ORF2 gene that contributes to changes in the virulence and
pathogenicity of PCV2, but the involvement of the whole virus
genome (Finsterbusch and Mankertz, 2009). Therefore, two hypoth-
eses that could explain the emergence of the PCV2 recombinant
mutants in this study can be proposed, in combination with the
results of previous research. (1) Natural genetic recombination may
occur between PCV2a and PCV2b of different genotypes in infected
animals. However, natural recombinant mutants have not been
isolated from pig herds in vivo to date, and recombination has only
been described from the sequences obtained from ﬁeld samples in
various studies (Cai et al., 2011; Cheung, 2009; Gagnon et al., 2010;
Hesse et al., 2008; Lefebvre et al., 2009; Ma et al., 2007; Olvera et al.,
2007). (2) In vitro, recombination occurs during co-infection with
different genotypes of PCV2 (PCV2a and PCV2b) in PK15 cells, with
Fig. 4.One-step growth curve of the two PCV2 recombinantmutants and their parental viruses in PK15 cells. The TCID50 for each virus was plotted, with bars showing the range of the
data and asterisks (*) indicating signiﬁcant differences. In general, compared with their parental backbones, PCV2b/JF11 and PCV2b/YJ, the two PCV2 recombinant mutants with
ORF2 replaced by that of the parental donor, PCV2a/CL1, showed increased replication efﬁciency when compared with those of any parental PCV2. The two PCV2 recombinant
mutants achieved signiﬁcantly higher infectivity titers than any parental PCV2 at 24, 48, 60, 72 and 84 h pi, and these differences were statistically signiﬁcant (Pb0.05), as
determined by the t-test.
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result of unknown mechanisms. Changes to the cell receptor of the
virus, due to variation in dimensions, may result from recombination
and exchange of ORF1 and ORF2 genes during infection. It is
speculated that different arrangements of ORF1 and ORF2 among
different genotypes of PCV2 may result in the large differences
observed in the virulence of PCV2.
In summary, the results from this study demonstrate that
exchange of ORF1 and ORF2 genes between different genotypes of
PCV2 occurred to produce new recombinant forms that showed
signiﬁcantly enhanced viral replication and altered antigenicity in
vitro. The ﬁndings of this study may facilitate future studies on the
differences in pathogenicity between the existing major genotypes
(PCV2a and PCV2b) and the two PCV2 recombinant mutants and may
contribute to the deeper understanding of the molecular epidemiol-
ogy of PCV2. The signiﬁcance of PCV2 in terms of recombinant
mutants needs further investigation, and additional studies are under
way to determine how the recombinant mutants act in modifying the
PCV2 phenotype.
Materials and methods
Cells and viruses
The porcine kidney cell line (PK15) was maintained at 37 °C with
5% CO2 in minimum essential medium (MEM) (Invitrogen, USA)
supplemented with 5% heat-inactivated fetal bovine serum (FBS),
100 IU/mL penicillin and 100 μg/mL streptomycin. Different geno-
types of representative strains of PCV2, which were termed PCV2a/
CL1, PCV2b/JF11 and PCV2b/YJ (all were at the 9th passage), withFig. 5. Phylogenetic tree based on the full-length genomic DNA sequences of PCV2 determine
PCV2a genotype;▲: PCV2b genotype and■: PCV2c genotype). The full-length genomic DNA
neighbor-joining (NJ) method with nucleotide distances (p-distance) and 1000 replication
changed from PCV2b to PCV2a, although their parental backbones, PCV2b/JF11 and PCV2b/YJ,
to the nomenclature proposed by Grau et al. (2008); Segalés et al. (2008) and Cortey et al.GenBank accession numbers JF682791, JF682792 and HM038032,
respectively, were maintained in the Harbin Veterinary Research
Institute. PCV2-positive sera from pigs infected with the PCV2a or
PCV2b genotype and porcine PCV2 negative sera were also prepared
and kept in the Harbin Veterinary Research Institute.
Co-infection of the two genotypes PCV2a and PCV2b
Co-infections with PCV2a and PCV2b, the two major genotypes of
PCV2, were performed in this study. The PCV2b representative strains
PCV2b/JF11 and PCV2b/YJ were selected and used to co-infect PK15
cells with the PCV2a representative strain (PCV2a/CL1). The parental
PCV2 virus titers for the co-infection experiment were all 103.5 TCID50,
respectively. The cells co-infected with virus were propagated by 10
consecutive passages in vitro. The virus cultures were harvested for
three freeze–thaw cycles, fragmented and centrifuged. The superna-
tant from each passagewas used as a template for PCR ampliﬁcation of
the viral full-length genome using PCV2-speciﬁc primers as described
previously (Guo et al., 2010). The full-length genomic PCR products
were cloned and 10 different clones were analyzed by sequencing the
full-length genome for each passage, according to a previously
described method (Guo et al., 2010). The existence of recombinant
mutants was detected by sequencing the full-length genome of the
ampliﬁed products from the 1st to the 10th passage. The mutants
were separated from the parental strains by the consecutive end-
point dilution method and were conﬁrmed by an immunoperoxidase
monolayer assay (IPMA) method using PCV2-positive sera from pigs
infected with PCV2a and PCV2b genotypes, respectively. For the
recombinant mutants obtained from the end-point dilution, the PCR
products were cloned and 10 different clones were analyzed by DNAd in this study, together with reference sequences of three different PCV2 genotypes (●:
sequences were aligned and the relationships between individuals were assessed by the
s in the bootstrap analysis. The genotypes of the two PCV2 recombinant mutants had
were both of the PCV2b genotype. These ﬁndings were based on classiﬁcation according
(2011).
Fig. 6. Reactivity of the two PCV2 recombinant mutants and their parental PCV2 strains with mAb 1D2 by capture ELISA. The results demonstrated strong reactivity of the two PCV2
recombinant mutants, similar to that of their parental donor PCV2a/CL1. However, the parental backbone strains (PCV2b/JF11 and PCV2b/YJ) of the PCV2 recombinantmutants were not
recognized by mAb 1D2, indicating that the PCV2 recombinant mutants had signiﬁcant antigenic changes when compared with their parental backbone (PCV2b/JF11 or PCV2b/YJ).
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2010).
Morphological observations by electron microscopy
The cultures of the two PCV2 recombinant mutants were mixed
with a 1:100 dilution of porcine anti-PCV2 positive sera (PCV2a),
incubated overnight at 4 °C, and centrifuged at 14,000×g for 30 min.
The immune complexes containing viral particles were harvested, and
morphological characterization of the recombinant mutants was
performed using electron microscopy (Hitachi, H-7650, Japan).
Comparison of the viral replication efﬁciency between the two PCV2
recombinant mutants and their parental strains
For growth characterization, PK15 cells seeded into 24-well plates
at 50% conﬂuence were infected with a 0.5 multiplicity of infection of
virus and incubated for 1 h at 37 °C. After washing three times with
PBS, 1 mL of MEMmediumwas added to each well. Triplicate wells of
infected cells for each virus were harvested every 12 h up to 96 h post-
infection (pi), frozen and thawed three times, clariﬁed at 3000×g at
4 °C for 10 min, and stored at −80 °C until titrated. At 12, 24, 36, 48,
60, 72, 84 and 96 h pi, the infectivity titers of each virus were
determined, as reported previously (Beach et al., 2010), and these
data were analyzed statistically (Pb0.05) using the t-test.
Phylogenetic tree analysis
In order to show the weight of the Cap gene variation in the full-
length genome sequence, Mega version 3.1 software (Kumar et al.,
2004) was used to align the full-length genomic DNA sequences
determined in this study with three different PCV2 genotype
reference sequences from the GenBank database (GenBank no.
AF055392 for PCV2a genotype; AF055394 for PCV2b genotype;
EU148503 for PCV2c genotype). Relationships between individualsTable 3
Differences in antigenicity between the recombinant mutants and their parental viruses
by neutralization assay.
Virus Sera from pigs infected with PCV2 and mAb 1D2
supernatant
PCV2a# PCV2b⁎ 1D2
PCV2a/CL1 1:12,800 1:1600 1:640
PCV2b/YJ 1:1600 1:3200 –
PCV2b/JF11 1:3200 1:6400 –
PCV2b(JF11)/2a(CL1) 1:6400 1:800 1:640
PCV2b(YJ)/2a(CL1) 1:6400 1:1600 1:640
Note: #: represents the sera from pigs infected with PCV2 of genotype PCV2a. ⁎:
represents the sera from pigs infected with PCV2 of genotype PCV2b. : indicates mAb
1D2 supernatant. –: indicates that there is no neutralization activity.were assessed by the neighbor-joining (NJ) method with nucleotide
distances (p-distance) and 1000 replications in the bootstrap analysis.Antigenic analysis by capture ELISA using mAb
A neutralizing mAb 1D2 against PCV2 Cap protein was prepared
previously (Huang et al., 2011). The mAb 1D2 recognizes a
conformational epitope and displays neutralization activity against
PCV2 as shown by a neutralization test (data not shown). For the
antigen capture ELISA, 96-well microtiter plates were coated with
anti-PCV2a. The ELISA results showed no signiﬁcant differences when
anti-PCV2 sera from pigs infected with the PCV2a or the PCV2b
genotype was used in the ELISA assay. Porcine positive sera (1:100
dilution) were incubated in 100 mmol/L carbonate buffer (pH 9.6) at
4 °C overnight, andwere blocked subsequently with 5% skimmedmilk
for 3 h. After blocking, the plates were washed three times with PBS-T
(PBS with 0.1% Tween 20). In the binding assay, plates were incubated
with the culture supernatant of the PCV2 viruses [104.0×50% tissue
culture infective dose (TCID50)/mL] at 37 °C for 1 h, followed by three
washes with PBS-T. Bound viruses were detected with horseradish
peroxidase (HRP)-coupled 1D2 mAb against the PCV2 Cap protein.
Subsequently, 100 μL of 2,2′-azino-bis[3-ethylbenzthiazoline-6-sul-
phonic acid] (ABTS)was added; after 30 min the reactionwas stopped
with 2 MH2SO4 and the absorbance at 405 nmwasmeasured using an
ELISA plate reader (Bio-Rad, Hercules, CA, USA).Sensitive serum neutralization assays
In order to determine the neutralizing activity of the PCV2-positive
sera from pigs infectedwith the PCV2a and PCV2b genotypes andmAb
1D2 against recombinant mutants as well as the parental strains,
respectively, a sensitive serum neutralization assay was adapted from
the method of Lefebvre et al. (2008). Brieﬂy, 103.3 TCID50 virus in a
volume of 200 μL was incubated for 1 h at 37 °C with an equal volume
of twofold serially diluted PCV2-positive sera (1: 100–1: 25,600) or
mAb 1D2 supernatant (1: 10–1: 1280). After incubation, this mixture
was added to semi-conﬂuent monolayers of PCV-negative PK15 cells
in four wells of a 96-well plate. After 1 h at 37 °C, the cell cultures
were washed twice with MEM and fresh medium was added. The cell
cultures were ﬁxed 36 h later. The IPMA was performed as described
by Huang et al. (2011) using PCV2-positive sera. The number of
infected cells per well was determined by light microscopy. The
neutralizing activity of the antibody was expressed as the percentage
reduction in the number of infected cells when compared with the
negative control. The neutralizing antibody titers were calculated as
the reciprocal of the last dilution in which the percentage reduction
was N50%. Assays were performed with the recombinant mutants and
their parental strains. In addition, PCV2-negative serum was used as a
negative control.
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